Zirconium-89-girentuximab PET/CT Imaging in Renal Cell Carcinoma
Status:
Completed
Trial end date:
2017-06-06
Target enrollment:
Participant gender:
Summary
Girentuximab is an antibody against Carbonic Anhydrase IX (CAIX), an antigen that is
expressed on the cell surface of 95% of clear cell RCC (ccRCC). Zr-89-girentuximab PET/CT
(Positron Emission Tomography) may be a valuable imaging technique in the diagnosis of
patients with RCC. The aim of the present study is to show the impact of the
Zr-89-girentuximab PET/CT on the clinical management of ccRCC patients.